Program News
News and stories about the UNC Lineberger Cellular Immunotherapy Program
-
Curated cancer care
UNC Lineberger researchers are using CAR-T to create better and personalized cancer treatments in one of the largest cell therapy facilities on the East Coast.
-
Thomas C. Shea Clinical Cancer Symposium brings together national leaders in blood cancers
The inaugural symposium featured talks on adoptive cellular therapy for lymphoid malignancies and novel approaches for the treatment of acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.
-
Questions and answers about CAR-T therapy
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
-
Parents, supporters create new fund for CAR-T therapy
Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.
-
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
-
European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
-
Excellent research results for CAR-T therapy against Hodgkin lymphoma
CAR-T immunotherapy has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical trial.
-
CAR-T therapy gives patient options after cancer returns
When traditional cancer treatment options failed, Sabrina Shelton’s care team referred her to UNC for a CAR-T therapy clinical trial.